BioVie Inc. (BIVI) 10-Year Financial Performance & Capital Metrics

BIVI • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutBioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.Show more

Revenue $0
EBITDA -$18M +44.2%
Net Income -$18M +45.4%
EPS (Diluted) -12.12 +83.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -101.64% +51.2%
ROIC -
Debt/Equity 0.02 -95.3%
Interest Coverage -54.30 -388.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 5 (bottom 5%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM27.54%

EPS CAGR

10Y-

5Y-

3Y-

TTM76.27%

ROCE

10Y Avg-443.46%

5Y Avg-703.82%

3Y Avg-175.32%

Latest-102.81%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	229.38K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0	0	0	-229.38K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-	-	-
Operating Expenses+	432.03K	1.55M	2.37M	2.5M	2.69M	138.05M	27.25M	45.08M	32.18M	17.84M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	343.09K	857.88K	1.77M	1.26M	0	0	0	11.55M	0	8.57M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	37.9K	466.35K	370.85K	1.01M	1.15M	133.19M	17.26M	33.3M	23.1M	9.27M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	222.93K	0	0	1.54M	4.87M	9.99M	229.38K	9.08M	0
Operating Income+	-432.03K	-1.55M	-2.37M	-2.5M	-2.69M	-138.05M	-27.25M	-45.08M	-32.18M	-18.07M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.85%	-2.6%	-0.53%	-0.05%	-0.08%	-50.27%	0.8%	-0.65%	0.29%	0.44%
EBITDA+	-380.99K	-1.32M	-2.14M	-2.27M	-2.46M	-137.82M	-27.02M	-44.85M	-31.95M	-17.84M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.64%	-2.48%	-0.62%	-0.06%	-0.09%	-54.95%	0.8%	-0.66%	0.29%	0.44%
D&A (Non-Cash Add-back)	51.04K	229.38K	229.38K	229.38K	229.38K	230K	229.38K	229.38K	229.38K	229.38K
EBIT	-431.84K	-1.55M	-2.37M	-2.5M	-2.69M	-138.05M	-27.25M	-45.96M	-32.18M	-17.21M
Net Interest Income+	105	0	-40.96K	886	-4.77M	-537.48K	-2.12M	-3.74M	-1.76M	520.31K
Interest Income	186	0	0	1.16K	0	21.97K	44.08K	562.26K	1.14M	853.03K
Interest Expense	0	0	40.96K	273	4.77M	559.46K	2.16M	4.3M	2.89M	332.72K
Other Income/Expense	105	222.94K	-40.96K	52.29K	-13.98M	7.8M	1.17M	-5.18M	59.05K	524.08K
Pretax Income+	-431.92K	-1.33M	-2.41M	-2.44M	-16.68M	-130.25M	-26.08M	-50.26M	-32.12M	-17.54M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-105	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-431.92K	-1.33M	-2.41M	-2.44M	-16.68M	-130.25M	-26.08M	-50.26M	-32.12M	-17.54M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.85%	-2.08%	-0.81%	-0.01%	-5.82%	-6.81%	0.8%	-0.93%	0.36%	0.45%
Net Income (Continuing)	-431.92K	-1.33M	-2.41M	-2.44M	-16.68M	-130.25M	-26.08M	-50.26M	-32.12M	-17.54M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-61.90	-186.10	-317.70	-98.20	-685.20	-1482.30	-106.00	-154.70	-73.05	-12.12
EPS Growth %	-0.85%	-2.01%	-0.71%	0.69%	-5.98%	-1.16%	0.93%	-0.46%	0.53%	0.83%
EPS (Basic)	-61.90	-186.10	-317.70	-98.20	-685.20	-1482.30	-106.00	-154.70	-73.05	-12.12
Diluted Shares Outstanding	6.98K	7.15K	7.66K	25.4K	49.3K	124.03K	246.63K	324.83K	451.85K	1.48M
Basic Shares Outstanding	6.9K	7.1K	7.5K	24.9K	49.3K	124.03K	246.63K	324.83K	451.85K	1.48M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	130.74K	5.14K	45.8K	674.07K	412.98K	4.61M	18.78M	34.04M	24.05M	20.7M
Cash & Short-Term Investments	123.76K	5.14K	45.8K	339.92K	37.2K	4.51M	18.64M	33.94M	23.84M	17.54M
Cash Only	123.76K	5.14K	45.8K	339.92K	37.2K	4.51M	18.64M	19.46M	23.84M	17.54M
Short-Term Investments	0	0	0	0	0	0	0	14.48M	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	2.1M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	334.15K	375.79K	0	0	102.53K	204.39K	0
Total Non-Current Assets+	2.59M	2.36M	2.13M	1.9M	1.67M	1.44M	1.33M	1.06M	1.16M	863.71K
Property, Plant & Equipment	2.59M	0	0	0	0	0	118.25K	80.79K	406.73K	339.65K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	345.71K	345.71K	345.71K	345.71K	345.71K	345.71K	345.71K	345.71K	345.71K	345.71K
Intangible Assets	2.24M	2.01M	1.78M	1.55M	1.33M	1.1M	866.47K	637.1K	407.72K	178.34K
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	-2.59M	0	0	0	0	0	4.56K	0	0	0
Total Assets+	2.72M	2.36M	2.18M	2.57M	2.08M	6.05M	20.11M	35.1M	25.21M	21.56M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	9.09%	-0.13%	-0.08%	0.18%	-0.19%	1.9%	2.33%	0.75%	-0.28%	-0.14%
Total Current Liabilities+	803.24K	630.97K	1.24M	443.48K	23.52M	996.37K	4.17M	14.49M	9.35M	2.27M
Accounts Payable	293.63K	470.97K	884.21K	443.48K	1.26M	996.37K	2.44M	0	0	2.2M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	3.5K
Short-Term Debt	10K	35K	0	0	848.54K	0	0	9.11M	5.7M	0
Deferred Revenue (Current)	-10K	-35K	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	21.41M	0	1.11M	5.34M	3.59M	0
Current Ratio	0.16x	0.01x	0.04x	1.52x	0.02x	4.62x	4.50x	2.35x	2.57x	9.10x
Quick Ratio	0.16x	0.01x	0.04x	1.52x	0.02x	4.62x	4.50x	2.35x	2.57x	9.10x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	575.92K	825.92K	0	62.5K	0	12.27M	5.27M	349.89K	275.43K
Long-Term Debt	0	575.92K	825.92K	0	62.5K	0	12.14M	5.23M	0	0
Capital Lease Obligations	0	0	0	0	0	0	87.41K	42.51K	349.89K	275.43K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	48.38K	0	0	0
Total Liabilities	803.25K	1.21M	2.06M	443.48K	23.58M	996.37K	16.44M	19.76M	9.7M	2.55M
Total Debt+	10K	35K	825.92K	0	911.04K	0	12.26M	14.42M	6.11M	349.89K
Net Debt	-113.76K	29.86K	780.12K	-339.92K	873.85K	-4.51M	-6.38M	-5.04M	-17.73M	-17.19M
Debt / Equity	0.01x	0.03x	7.43x	-	-	-	3.34x	0.94x	0.39x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-57.91x	-9146.52x	-0.56x	-246.77x	-12.60x	-10.48x	-11.12x	-54.30x
Total Equity+	1.92M	1.16M	111.2K	2.13M	-21.5M	5.05M	3.67M	15.34M	15.51M	19.01M
Equity Growth %	36.4%	-0.4%	-0.9%	18.16%	-11.09%	1.23%	-0.27%	3.18%	0.01%	0.23%
Book Value per Share	274.65	161.83	14.52	83.91	-436.12	40.72	14.88	47.23	34.32	12.87
Total Shareholders' Equity	1.92M	1.16M	111.2K	2.13M	-21.5M	5.05M	3.67M	15.34M	15.51M	19.01M
Common Stock	8.72K	9.19K	9.85K	50.73K	520	2.23K	2.5K	3.64K	6.23K	7.48K
Retained Earnings	-1M	-2.34M	-4.77M	-7.26M	-41.04M	-224.89M	-250.97M	-301.23M	-334.23M	-352.14M
Treasury Stock	0	0	0	0	0	0	0	-2	-27	-29
Accumulated OCI	0	0	0	0	0	0	0	176.59K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-163.63K	-623.62K	-621.34K	-2.5M	-1.63M	-10.45M	-18.99M	-40.25M	-27.95M	-19.03M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.5%	-2.81%	0%	-3.03%	0.35%	-5.42%	-0.82%	-1.12%	0.31%	0.32%
Net Income	-431.92K	-1.33M	-2.41M	-2.44M	-16.68M	-130.25M	-26.08M	-50.26M	-32.12M	-17.54M
Depreciation & Amortization	51.04K	229.38K	229.38K	229.38K	229.38K	229.38K	229.38K	229.38K	229.38K	229.38K
Stock-Based Compensation	7.88K	92.05K	893.48K	64.86K	24.85K	3.02M	6.19M	6.38M	0	2.47M
Deferred Taxes	4.91K	0	0	51.4K	0	-8.34M	0	-1.03B	0	0
Other Non-Cash Items	-10K	550.81K	26.52K	49K	14.02M	124.87M	-2.08M	1.04B	4.03M	212.09K
Working Capital Changes	214.47K	385.63K	642.4K	-451.93K	774.09K	19.47K	2.75M	-270.44K	-86.84K	-4.4M
Change in Receivables	0	0	0	0	0	0	0	0	0	-2.1M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	42.79K	350.67K	413.23K	-117.78K	0	0	0	0	0	0
Cash from Investing+	9.91K	0	0	0	0	0	0	-14.3M	14.53M	0
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	9.91K	0	0	0	0	0	0	0	0	0
Cash from Financing+	0	505K	662K	2.8M	1.33M	14.93M	33.12M	55.37M	17.8M	12.73M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-48.66K	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	505K	250K	3.04M	0	685.3K	0	2.24K	0	2.9M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-163.63K	-623.62K	-621.34K	-2.5M	-1.63M	-10.45M	-18.99M	-40.25M	-27.95M	-19.03M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.5%	-2.81%	0%	-3.03%	0.35%	-5.42%	-0.82%	-1.12%	0.31%	0.32%
FCF per Share	-23.46	-87.20	-81.11	-98.50	-33.03	-84.28	-77.00	-123.92	-61.85	-12.88
FCF Conversion (FCF/Net Income)	0.38x	0.47x	0.26x	1.02x	0.10x	0.08x	0.73x	0.80x	0.87x	1.08x
Interest Paid	0	0	0	0	3.09K	22.18K	964.24K	2.11M	0	183.93K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-46.4%	-86.62%	-380.44%	-218.01%	-	-2579.03%	-598.18%	-528.7%	-208.26%	-101.64%
Return on Invested Capital (ROIC)	-43.77%	-77.98%	-171.18%	-139.64%	-	-	-	-890.52%	-597.91%	-
Debt / Equity	0.01x	0.03x	7.43x	-	-	-	3.34x	0.94x	0.39x	0.02x
Interest Coverage	-	-	-57.91x	-9146.52x	-0.56x	-246.77x	-12.60x	-10.48x	-11.12x	-54.30x
FCF Conversion	0.38x	0.47x	0.26x	1.02x	0.10x	0.08x	0.73x	0.80x	0.87x	1.08x

Frequently Asked Questions

Growth & Financials

BioVie Inc. (BIVI) grew revenue by 0.0% over the past year. Growth has been modest.

BioVie Inc. (BIVI) reported a net loss of $18.5M for fiscal year 2025.

Dividend & Returns

BioVie Inc. (BIVI) has a return on equity (ROE) of -101.6%. Negative ROE indicates the company is unprofitable.

BioVie Inc. (BIVI) had negative free cash flow of $18.5M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

BioVie Inc. (BIVI) 10-Year Financial Performance & Capital Metrics

BIVI • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

Revenue $0
EBITDA -$18M +44.2%
Net Income -$18M +45.4%
EPS (Diluted) -12.12 +83.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -101.64% +51.2%
ROIC -
Debt/Equity 0.02 -95.3%
Interest Coverage -54.30 -388.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 5 (bottom 5%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM27.54%

EPS CAGR

10Y-

5Y-

3Y-

TTM76.27%

ROCE

10Y Avg-443.46%

5Y Avg-703.82%

3Y Avg-175.32%

Latest-102.81%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	229.38K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0	0	0	-229.38K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-	-	-
Operating Expenses+	432.03K	1.55M	2.37M	2.5M	2.69M	138.05M	27.25M	45.08M	32.18M	17.84M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	343.09K	857.88K	1.77M	1.26M	0	0	0	11.55M	0	8.57M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	37.9K	466.35K	370.85K	1.01M	1.15M	133.19M	17.26M	33.3M	23.1M	9.27M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	222.93K	0	0	1.54M	4.87M	9.99M	229.38K	9.08M	0
Operating Income+	-432.03K	-1.55M	-2.37M	-2.5M	-2.69M	-138.05M	-27.25M	-45.08M	-32.18M	-18.07M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.85%	-2.6%	-0.53%	-0.05%	-0.08%	-50.27%	0.8%	-0.65%	0.29%	0.44%
EBITDA+	-380.99K	-1.32M	-2.14M	-2.27M	-2.46M	-137.82M	-27.02M	-44.85M	-31.95M	-17.84M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.64%	-2.48%	-0.62%	-0.06%	-0.09%	-54.95%	0.8%	-0.66%	0.29%	0.44%
D&A (Non-Cash Add-back)	51.04K	229.38K	229.38K	229.38K	229.38K	230K	229.38K	229.38K	229.38K	229.38K
EBIT	-431.84K	-1.55M	-2.37M	-2.5M	-2.69M	-138.05M	-27.25M	-45.96M	-32.18M	-17.21M
Net Interest Income+	105	0	-40.96K	886	-4.77M	-537.48K	-2.12M	-3.74M	-1.76M	520.31K
Interest Income	186	0	0	1.16K	0	21.97K	44.08K	562.26K	1.14M	853.03K
Interest Expense	0	0	40.96K	273	4.77M	559.46K	2.16M	4.3M	2.89M	332.72K
Other Income/Expense	105	222.94K	-40.96K	52.29K	-13.98M	7.8M	1.17M	-5.18M	59.05K	524.08K
Pretax Income+	-431.92K	-1.33M	-2.41M	-2.44M	-16.68M	-130.25M	-26.08M	-50.26M	-32.12M	-17.54M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-105	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-431.92K	-1.33M	-2.41M	-2.44M	-16.68M	-130.25M	-26.08M	-50.26M	-32.12M	-17.54M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.85%	-2.08%	-0.81%	-0.01%	-5.82%	-6.81%	0.8%	-0.93%	0.36%	0.45%
Net Income (Continuing)	-431.92K	-1.33M	-2.41M	-2.44M	-16.68M	-130.25M	-26.08M	-50.26M	-32.12M	-17.54M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-61.90	-186.10	-317.70	-98.20	-685.20	-1482.30	-106.00	-154.70	-73.05	-12.12
EPS Growth %	-0.85%	-2.01%	-0.71%	0.69%	-5.98%	-1.16%	0.93%	-0.46%	0.53%	0.83%
EPS (Basic)	-61.90	-186.10	-317.70	-98.20	-685.20	-1482.30	-106.00	-154.70	-73.05	-12.12
Diluted Shares Outstanding	6.98K	7.15K	7.66K	25.4K	49.3K	124.03K	246.63K	324.83K	451.85K	1.48M
Basic Shares Outstanding	6.9K	7.1K	7.5K	24.9K	49.3K	124.03K	246.63K	324.83K	451.85K	1.48M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	130.74K	5.14K	45.8K	674.07K	412.98K	4.61M	18.78M	34.04M	24.05M	20.7M
Cash & Short-Term Investments	123.76K	5.14K	45.8K	339.92K	37.2K	4.51M	18.64M	33.94M	23.84M	17.54M
Cash Only	123.76K	5.14K	45.8K	339.92K	37.2K	4.51M	18.64M	19.46M	23.84M	17.54M
Short-Term Investments	0	0	0	0	0	0	0	14.48M	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	2.1M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	334.15K	375.79K	0	0	102.53K	204.39K	0
Total Non-Current Assets+	2.59M	2.36M	2.13M	1.9M	1.67M	1.44M	1.33M	1.06M	1.16M	863.71K
Property, Plant & Equipment	2.59M	0	0	0	0	0	118.25K	80.79K	406.73K	339.65K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	345.71K	345.71K	345.71K	345.71K	345.71K	345.71K	345.71K	345.71K	345.71K	345.71K
Intangible Assets	2.24M	2.01M	1.78M	1.55M	1.33M	1.1M	866.47K	637.1K	407.72K	178.34K
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	-2.59M	0	0	0	0	0	4.56K	0	0	0
Total Assets+	2.72M	2.36M	2.18M	2.57M	2.08M	6.05M	20.11M	35.1M	25.21M	21.56M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	9.09%	-0.13%	-0.08%	0.18%	-0.19%	1.9%	2.33%	0.75%	-0.28%	-0.14%
Total Current Liabilities+	803.24K	630.97K	1.24M	443.48K	23.52M	996.37K	4.17M	14.49M	9.35M	2.27M
Accounts Payable	293.63K	470.97K	884.21K	443.48K	1.26M	996.37K	2.44M	0	0	2.2M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	3.5K
Short-Term Debt	10K	35K	0	0	848.54K	0	0	9.11M	5.7M	0
Deferred Revenue (Current)	-10K	-35K	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	21.41M	0	1.11M	5.34M	3.59M	0
Current Ratio	0.16x	0.01x	0.04x	1.52x	0.02x	4.62x	4.50x	2.35x	2.57x	9.10x
Quick Ratio	0.16x	0.01x	0.04x	1.52x	0.02x	4.62x	4.50x	2.35x	2.57x	9.10x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	575.92K	825.92K	0	62.5K	0	12.27M	5.27M	349.89K	275.43K
Long-Term Debt	0	575.92K	825.92K	0	62.5K	0	12.14M	5.23M	0	0
Capital Lease Obligations	0	0	0	0	0	0	87.41K	42.51K	349.89K	275.43K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	48.38K	0	0	0
Total Liabilities	803.25K	1.21M	2.06M	443.48K	23.58M	996.37K	16.44M	19.76M	9.7M	2.55M
Total Debt+	10K	35K	825.92K	0	911.04K	0	12.26M	14.42M	6.11M	349.89K
Net Debt	-113.76K	29.86K	780.12K	-339.92K	873.85K	-4.51M	-6.38M	-5.04M	-17.73M	-17.19M
Debt / Equity	0.01x	0.03x	7.43x	-	-	-	3.34x	0.94x	0.39x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-57.91x	-9146.52x	-0.56x	-246.77x	-12.60x	-10.48x	-11.12x	-54.30x
Total Equity+	1.92M	1.16M	111.2K	2.13M	-21.5M	5.05M	3.67M	15.34M	15.51M	19.01M
Equity Growth %	36.4%	-0.4%	-0.9%	18.16%	-11.09%	1.23%	-0.27%	3.18%	0.01%	0.23%
Book Value per Share	274.65	161.83	14.52	83.91	-436.12	40.72	14.88	47.23	34.32	12.87
Total Shareholders' Equity	1.92M	1.16M	111.2K	2.13M	-21.5M	5.05M	3.67M	15.34M	15.51M	19.01M
Common Stock	8.72K	9.19K	9.85K	50.73K	520	2.23K	2.5K	3.64K	6.23K	7.48K
Retained Earnings	-1M	-2.34M	-4.77M	-7.26M	-41.04M	-224.89M	-250.97M	-301.23M	-334.23M	-352.14M
Treasury Stock	0	0	0	0	0	0	0	-2	-27	-29
Accumulated OCI	0	0	0	0	0	0	0	176.59K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-163.63K	-623.62K	-621.34K	-2.5M	-1.63M	-10.45M	-18.99M	-40.25M	-27.95M	-19.03M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.5%	-2.81%	0%	-3.03%	0.35%	-5.42%	-0.82%	-1.12%	0.31%	0.32%
Net Income	-431.92K	-1.33M	-2.41M	-2.44M	-16.68M	-130.25M	-26.08M	-50.26M	-32.12M	-17.54M
Depreciation & Amortization	51.04K	229.38K	229.38K	229.38K	229.38K	229.38K	229.38K	229.38K	229.38K	229.38K
Stock-Based Compensation	7.88K	92.05K	893.48K	64.86K	24.85K	3.02M	6.19M	6.38M	0	2.47M
Deferred Taxes	4.91K	0	0	51.4K	0	-8.34M	0	-1.03B	0	0
Other Non-Cash Items	-10K	550.81K	26.52K	49K	14.02M	124.87M	-2.08M	1.04B	4.03M	212.09K
Working Capital Changes	214.47K	385.63K	642.4K	-451.93K	774.09K	19.47K	2.75M	-270.44K	-86.84K	-4.4M
Change in Receivables	0	0	0	0	0	0	0	0	0	-2.1M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	42.79K	350.67K	413.23K	-117.78K	0	0	0	0	0	0
Cash from Investing+	9.91K	0	0	0	0	0	0	-14.3M	14.53M	0
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	9.91K	0	0	0	0	0	0	0	0	0
Cash from Financing+	0	505K	662K	2.8M	1.33M	14.93M	33.12M	55.37M	17.8M	12.73M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-48.66K	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	505K	250K	3.04M	0	685.3K	0	2.24K	0	2.9M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-163.63K	-623.62K	-621.34K	-2.5M	-1.63M	-10.45M	-18.99M	-40.25M	-27.95M	-19.03M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.5%	-2.81%	0%	-3.03%	0.35%	-5.42%	-0.82%	-1.12%	0.31%	0.32%
FCF per Share	-23.46	-87.20	-81.11	-98.50	-33.03	-84.28	-77.00	-123.92	-61.85	-12.88
FCF Conversion (FCF/Net Income)	0.38x	0.47x	0.26x	1.02x	0.10x	0.08x	0.73x	0.80x	0.87x	1.08x
Interest Paid	0	0	0	0	3.09K	22.18K	964.24K	2.11M	0	183.93K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-46.4%	-86.62%	-380.44%	-218.01%	-	-2579.03%	-598.18%	-528.7%	-208.26%	-101.64%
Return on Invested Capital (ROIC)	-43.77%	-77.98%	-171.18%	-139.64%	-	-	-	-890.52%	-597.91%	-
Debt / Equity	0.01x	0.03x	7.43x	-	-	-	3.34x	0.94x	0.39x	0.02x
Interest Coverage	-	-	-57.91x	-9146.52x	-0.56x	-246.77x	-12.60x	-10.48x	-11.12x	-54.30x
FCF Conversion	0.38x	0.47x	0.26x	1.02x	0.10x	0.08x	0.73x	0.80x	0.87x	1.08x

Frequently Asked Questions

Growth & Financials

BioVie Inc. (BIVI) grew revenue by 0.0% over the past year. Growth has been modest.

BioVie Inc. (BIVI) reported a net loss of $18.5M for fiscal year 2025.

Dividend & Returns

BioVie Inc. (BIVI) has a return on equity (ROE) of -101.6%. Negative ROE indicates the company is unprofitable.

BioVie Inc. (BIVI) had negative free cash flow of $18.5M in fiscal year 2025, likely due to heavy capital investments.